Piramal Pharma Limited Announces Results for Q4 and Full-year FY26 USA - English USA - English
MUMBAI, India, April 28, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31 st March 2026.
Consolidated Financial Highlights
(in ₹ Crores or as stated)
Particulars
Q4FY26
Q4FY25
YoY %
FY26
FY25
YoY %
Revenue from Operations
2,752
2,754
(0) %
8,869
9,151
(3) %
CDMO
1,708
1,788
(4) %
4,915
5,447
(10) %
CHG
755
705
7 %
2,703
2,633
3 %
PCH
320
274
17 %
1,274
1,093
17 %
EBITDA
507
603
(16) %
1,135
1,580
(28) %
EBITDA Margin
18 %
22 %
13 %
17 %
PAT Before Expectational Item
167
154
9 %
(130)
91
NM
Exceptional Item 1
(176)
-
NM
(196)
-
NM
PAT After Expectational Item
(9)
154
NM
(326)
91
NM
1. During the quarter, the management has recognized an impairment loss of ₹. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment. Accordingly, the carrying amount has been written down in full.
Key Highlights
Nandini Piramal, Chairperson, Piramal Pharma Limited said, "FY26 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses. The meaningful recovery in biopharma funding seen from Sep'25, is translating into good RFP momentum and healthy pick up in order inflows in our CDMO business. In the CHG business, the recently completed Kenalog® acquisition alongside ramp up of inhalation anesthesia sales in ex-US markets are expected to be key growth drivers. Our Consumer Healthcare business is also well positioned to sustain its growth momentum with margin improvement driven by Power Brands and rapid growth in e‑commerce.
Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT."
Key Business Highlights
Contract Development and Manufacturing Organization (CDMO):
Complex Hospital Generics (CHG):
Piramal Consumer Healthcare (PCH):
Consolidated Profit and Loss Statement
(in ₹ Crores or as stated)
Particulars
Quarterly
Full-year
Q4FY26
Q4FY25
YoY %
Q3FY26
QoQ %
FY26
FY25
YoY %
Revenue from Operations
2,752
2,754
(0) %
2,140
29 %
8,869
9,151
(3) %
Other Income
46
42
10 %
43
7 %
213
135
58 %
Total Income
2,798
2,796
0 %
2,183
28 %
9,082
9,286
(2) %
Material Cost
1,056
955
11 %
786
34 %
3,239
3,232
0 %
Employee Expenses
586
612
(4) %
600
(2) %
2,416
2,307
5 %
Other Expenses
650
626
4 %
558
16 %
2,293
2,167
6 %
EBITDA
507
603
(16) %
239
112 %
1,135
1,580
(28) %
Interest Expenses
83
104
(20) %
89
(7) %
341
422
(19) %
Depreciation
218
243
(10) %
213
3 %
831
816
2 %
Share of Net Profit of Associates
14
16
(16) %
10
32 %
57
73
(22) %
Profit Before Tax
219
273
(20) %
(53)
NM
20
415
(95) %
Tax
52
119
(57) %
42
22 %
150
324
(54) %
Net Profit after Tax
167
154
9 %
(95)
NM
(130)
91
NM
Exceptional item1
(176)
-
NM
(41)
NM
(196)
-
NM
Net Profit after Tax after Exceptional Item
(9)
154
NM
(136)
NM
(326)
91
NM
Consolidated Balance Sheet
(in ₹ Cr.)
Key Balance Sheet Items
As at
31-Mar-26
31-Mar-25
Total Equity
8,162
8,125
Net Debt
4,140
4,199
Total
12,302
12,324
Net Fixed Assets
9,784
9,110
Tangible Assets
4,843
4,534
Intangible Assets including goodwill
3,841
3,599
CWIP (including IAUD2)
1,100
977
Net Working Capital
2,057
2,798
Other Assets3
462
416
Total Assets
12,302
12,324
2. IAUD – Intangible Assets Under Development; 3. Other Assets include Investments and Deferred Tax Assets (Net)
Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 29 th April 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and full-year FY26 Results.
The dial-in details for the call are as under:
Event
Location & Time
Telephone Number
Conference call on 29 th April 2026
India – 09:30 AM IST
+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
1 800 120 1221 (Toll free number)
USA – 12:00 AM
(Eastern Time – New York)
Toll free number
18667462133
UK – 05:00 AM
(London Time)
Toll free number
08081011573
Singapore – 12:00 PM
(Singapore Time)
Toll free number
8001012045
Hong Kong – 12:00 PM
(Hong Kong Time)
Toll free number
800964448
Express Join with Diamond Pass™
Please use this link for prior registration to reduce wait time at the time of joining the call – Click here
About Piramal Pharma Limited:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 1 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.
For more information, visit: Piramal Pharma | LinkedIn
1. Includes one facility via PPL's minority investment in Yapan Bio.
Logo - https://mma.prnewswire.com/media/1855206/5942698/Piramal_Pharma_Limited_Logo.jpg